Positions Enzo Labs as “Center of Excellence” for Developing DiaSorin
NEW YORK--(BUSINESS WIRE)--
Enzo Biochem, Inc. (NYSE:ENZ) today announced its Enzo Clinical Labs
unit has entered into a collaboration with Italy-based DiaSorin, a
global leader in the field of biotechnologies, that will enable the Lab
to provide physician-clients in metropolitan New York with advanced
diagnostic tools and will also serve to evaluate new DiaSorin offerings
in the future.
“Our agreement with DiaSorin has multiple benefits that, in addition to
providing additional cutting edge diagnostic technology to physicians
and their patients from a global leader in the in vitro diagnostics
field, also reflects an acknowledgement of the excellent and expanding
capabilities of our Lab, a center of excellence, in evolving medical
science,” said Barry Weiner, Enzo President.
As part of the agreement, Enzo Clinical Labs has added two new DiaSorin
LIAISON® XL Analyzers, a new high throughput, chemiluminescent, random
access analyzer that provides a menu of over 30 assays. The system
requires no daily maintenance with most tests and can manage up to 25
different assays on board.
“We are excited to collaborate with Enzo to provide high quality
automated testing solutions to best serve their clients with an
opportunity for growth and improved patient care,” said John Eskdale,
DiaSorin President. “The LIAISON® XL, with its expanded menu, will offer
Enzo a competitive advantage in the areas of specialty testing which
include infectious disease, growth, hypertension, and bone & mineral.”
Enzo Labs initially will offer a number of DiaSorin LIAISON® XL tests to
its customers, including the LIAISON® 25 OH Vitamin D TOTAL assay, which
measures both 25-OH D2 and 25-OH D3 metabolites to
accurately assess Vitamin D sufficiency. Enzo will also offer DiaSorin’s
CMV IgM and Borrelia burgdorferi assays, and is currently
evaluating the company’s new LIAISON® Direct Renin and Aldosterone
assays. These tests are the only fully automated, FDA cleared
chemiluminescent assays available for the diagnosis and treatment of
certain types of hypertension and primary aldosteronism.
Enzo and DiaSorin will continue to evaluate the entire line of LIAISON®
assays to assure Enzo’s clientele of the availability of the most
advanced and high quality immunoassays.
About Enzo Biochem
Enzo Biochem is a pioneer in molecular diagnostics, leading the
convergence of clinical laboratories, life sciences and therapeutics
through the development of unique diagnostic platform technologies that
provide numerous advantages over previous standards. A global company,
Enzo Biochem utilizes cross-functional teams to develop and deploy
products systems and services that meet the ever-changing and rapidly
growing needs of health care both today and into the future.
Underpinning Enzo Biochem’s products and technologies is a broad and
deep intellectual property portfolio, with patent coverage across a
number of key enabling technologies.
For over 40 years, DiaSorin Company has been developing, manufacturing
and marketing reagent kits for in vitro diagnostics worldwide, and
offers the broadest range of specialty tests available in the
immunodiagnostics market. DiaSorin’s menu is unique for its breadth and
presence of specialty tests which identify DiaSorin as "the" in vitro
diagnostics specialist, and it is the exclusive supplier of the LIAISON®
platform, a closed system based on chemiluminescent technology that is
fully automated. The Company continually invests in research and
development, using its own distinctive expertise in the field of
immunodiagnostics to deliver a high level of innovation.
Except for historical information, the matters discussed in this news
release may be considered "forward-looking" statements within the
meaning of Section 27A of the Securities Act of 1933, as amended and
Section 21E of the Securities Exchange Act of 1934, as amended. Such
statements include declarations regarding the intent, belief or current
expectations of the Company and its management, including those related
to cash flow, gross margins, revenues, and expenses are dependent on a
number of factors outside of the control of the company including, inter
alia, the markets for the Company’s products and services, costs of
goods and services, other expenses, government regulations, litigations,
and general business conditions. See Risk Factors in the Company’s Form
10-K for the fiscal year ended July 31, 2013. Investors are cautioned
that any such forward-looking statements are not guarantees of future
performance and involve a number of risks and uncertainties that could
materially affect actual results. The Company disclaims any obligations
to update any forward-looking statement as a result of developments
occurring after the date of this press release.
For Enzo Biochem, Inc.
Anreder & Company
Michael Wachs, 212-732-4300
Riccardo Fava, +39.0161.487988
Head of IR and Media
Investor Relations Specialist
Source: Enzo Biochem, Inc.